Jacobs & CO Gilead Sciences, Inc. Transaction History

Jacobs & CO

$1 Billion
Q3 2024

A detailed history of Jacobs & CO transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Jacobs & CO holds 5,745 shares of GILD stock, worth $515,671. This represents 0.05% of its overall portfolio holdings.

Number of Shares

5,745

Previous 10,622 45.91%

Holding current value

$515,671

Previous $728,000 33.93%

% of portfolio

0.05%

Previous 0.08%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 01, 2024	SELL	$66.59 - $83.99 $324,759 - $409,619	-4,877 Reduced 45.91%	5,745 $481,000
Q2 2024 Jul 12, 2024	SELL	$63.15 - $72.88 $1.05 Million - $1.21 Million	-16,640 Reduced 61.04%	10,622 $728,000
Q1 2024 Apr 12, 2024	BUY	$71.58 - $87.29 $51,895 - $63,285	725 Added 2.73%	27,262 $2 Million
Q4 2023 Jan 17, 2024	SELL	$73.27 - $83.09 $57,443 - $65,142	-784 Reduced 2.87%	26,537 $2.15 Million
Q3 2023 Oct 13, 2023	BUY	$73.94 - $80.67 $2,587 - $2,823	35 Added 0.13%	27,321 $2.05 Million
Q2 2023 Jul 11, 2023	BUY	$76.01 - $86.7 $7,981 - $9,103	105 Added 0.39%	27,286 $2.1 Million
Q1 2023 Apr 17, 2023	BUY	$77.31 - $88.08 $15,075 - $17,175	195 Added 0.72%	27,181 $2.26 Million
Q4 2022 Jan 13, 2023	BUY	$62.32 - $89.47 $7,914 - $11,362	127 Added 0.47%	26,986 $2.32 Million
Q3 2022 Oct 11, 2022	BUY	$59.54 - $68.01 $33,342 - $38,085	560 Added 2.13%	26,859 $1.66 Million
Q2 2022 Jul 19, 2022	BUY	$57.72 - $65.01 $44,733 - $50,382	775 Added 3.04%	26,299 $1.63 Million
Q1 2022 Apr 14, 2022	BUY	$57.92 - $72.58 $106,283 - $133,184	1,835 Added 7.75%	25,524 $1.52 Million
Q4 2021 Jan 21, 2022	SELL	$64.88 - $73.64 $285,472 - $324,016	-4,400 Reduced 15.66%	23,689 $1.72 Million
Q2 2021 Jul 15, 2021	BUY	$63.47 - $69.35 $33,321 - $36,408	525 Added 1.9%	28,089 $1.93 Million
Q1 2021 Apr 05, 2021	SELL	$60.0 - $68.46 $67,200 - $76,675	-1,120 Reduced 3.9%	27,564 $1.78 Million
Q4 2020 Jan 12, 2021	BUY	$56.65 - $64.55 $41,637 - $47,444	735 Added 2.63%	28,684 $1.67 Million
Q3 2020 Dec 03, 2020	BUY	$62.1 - $78.08 $347,449 - $436,857	5,595 Added 25.03%	27,949 $1.77 Million
Q2 2020 Jul 09, 2020	BUY	$72.34 - $84.0 $151,914 - $176,400	2,100 Added 10.37%	22,354 $1.72 Million
Q1 2020 Apr 13, 2020	SELL	$62.63 - $80.22 $9,394 - $12,033	-150 Reduced 0.74%	20,254 $1.51 Million
Q4 2019 Jan 29, 2020	SELL	$61.62 - $67.78 $52,192 - $57,409	-847 Reduced 3.99%	20,404 $1.33 Million
Q3 2019 Nov 04, 2019	SELL	$62.51 - $69.0 $125,207 - $138,207	-2,003 Reduced 8.61%	21,251 $1.35 Million
Q2 2019 Aug 01, 2019	SELL	$61.87 - $69.38 $23,819 - $26,711	-385 Reduced 1.63%	23,254 $1.57 Million
Q1 2019 Apr 29, 2019	SELL	$62.53 - $70.05 $95,983 - $107,526	-1,535 Reduced 6.1%	23,639 $1.54 Million
Q4 2018 Feb 07, 2019	BUY	$60.54 - $79.0 $2,663 - $3,476	44 Added 0.18%	25,174 $1.58 Million
Q3 2018 Oct 23, 2018	SELL	$71.28 - $78.92 $207,210 - $229,420	-2,907 Reduced 10.37%	25,130 $1.94 Million
Q2 2018 Jul 19, 2018	SELL	$64.88 - $75.68 $8,434 - $9,838	-130 Reduced 0.46%	28,037 $1.99 Million
Q1 2018 Apr 30, 2018	BUY	$72.84 - $88.8 $21,487 - $26,196	295 Added 1.06%	28,167 $2.12 Million
Q4 2017 Feb 09, 2018	SELL	$71.15 - $83.52 $14,230 - $16,704	-200 Reduced 0.71%	27,872 $2 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $2.02 Million - $2.4 Million	28,072	28,072 $2.27 Million

Others Institutions Holding GILD

# of Institutions

1,924

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs & CO with notifications on news.

Account